BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 10632320)

  • 1. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
    Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G
    Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PTHrP and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients].
    Loibl S; Königs A; Kaufmann M; Costa SD; Bischoff J
    Zentralbl Gynakol; 2006 Dec; 128(6):330-5. PubMed ID: 17213971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.
    Woitge HW; Pecherstorfer M; Horn E; Keck AV; Diel IJ; Bayer P; Ludwig H; Ziegler R; Seibel MJ
    Br J Cancer; 2001 Feb; 84(3):344-51. PubMed ID: 11161399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers.
    Waltregny D; Bellahcène A; de Leval X; Florkin B; Weidle U; Castronovo V
    J Bone Miner Res; 2000 May; 15(5):834-43. PubMed ID: 10804012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development.
    Bellahcene A; Kroll M; Liebens F; Castronovo V
    J Bone Miner Res; 1996 May; 11(5):665-70. PubMed ID: 9157781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer.
    Jukkola A; Bloigu R; Holli K; Joensuu H; Valavaara R; Risteli J; Blanco G
    Anticancer Res; 2001; 21(4B):2873-6. PubMed ID: 11712779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
    Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
    Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
    Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum tumor markers in skeletal metastasis.
    Tsukushi S; Katagiri H; Kataoka T; Nishida Y; Ishiguro N
    Jpn J Clin Oncol; 2006 Jul; 36(7):439-44. PubMed ID: 16815865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole.
    Martinetti A; Bajetta E; Ferrari L; Zilembo N; Seregni E; Del Vecchio M; Longarini R; La Torre I; Toffolatti L; Paleari D; Bombardieri E
    Endocr Relat Cancer; 2004 Dec; 11(4):771-9. PubMed ID: 15613451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study.
    Papotti M; Kalebic T; Volante M; Chiusa L; Bacillo E; Cappia S; Lausi P; Novello S; Borasio P; Scagliotti GV
    J Clin Oncol; 2006 Oct; 24(30):4818-24. PubMed ID: 17050866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of bone matrix proteins in human breast cancer: potential roles in microcalcification formation and in the genesis of bone metastases.
    Bellahcène A; Castronovo V
    Bull Cancer; 1997 Jan; 84(1):17-24. PubMed ID: 9180854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
    Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
    Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
    Diel IJ; Solomayer EF; Costa SD; Gollan C; Goerner R; Wallwiener D; Kaufmann M; Bastert G
    N Engl J Med; 1998 Aug; 339(6):357-63. PubMed ID: 9691101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
    Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
    Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
    Scorilas A; Talieri M; Ardavanis A; Courtis N; Dimitriadis E; Yotis J; Tsiapalis CM; Trangas T
    Cancer Res; 2000 Oct; 60(19):5427-33. PubMed ID: 11034084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
    Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W
    Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.